These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 29298160)

  • 1. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
    Sullivan KM; Goldmuntz EA; Keyes-Elstein L; McSweeney PA; Pinckney A; Welch B; Mayes MD; Nash RA; Crofford LJ; Eggleston B; Castina S; Griffith LM; Goldstein JS; Wallace D; Craciunescu O; Khanna D; Folz RJ; Goldin J; St Clair EW; Seibold JR; Phillips K; Mineishi S; Simms RW; Ballen K; Wener MH; Georges GE; Heimfeld S; Hosing C; Forman S; Kafaja S; Silver RM; Griffing L; Storek J; LeClercq S; Brasington R; Csuka ME; Bredeson C; Keever-Taylor C; Domsic RT; Kahaleh MB; Medsger T; Furst DE;
    N Engl J Med; 2018 Jan; 378(1):35-47. PubMed ID: 29298160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
    Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
    Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis.
    Burt RK; Oliveira MC; Shah SJ; Moraes DA; Simoes B; Gheorghiade M; Schroeder J; Ruderman E; Farge D; Chai ZJ; Marjanovic Z; Jain S; Morgan A; Milanetti F; Han X; Jovanovic B; Helenowski IB; Voltarelli J
    Lancet; 2013 Mar; 381(9872):1116-24. PubMed ID: 23363664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stem cell transplantation for systemic sclerosis.
    Bruera S; Sidanmat H; Molony DA; Mayes MD; Suarez-Almazor ME; Krause K; Lopez-Olivo MA
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD011819. PubMed ID: 35904231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan.
    Ayano M; Tsukamoto H; Mitoma H; Kimoto Y; Akahoshi M; Arinobu Y; Miyamoto T; Horiuchi T; Niiro H; Nagafuji K; Harada M; Akashi K
    Arthritis Res Ther; 2019 Jan; 21(1):30. PubMed ID: 30670057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party.
    Henes J; Oliveira MC; Labopin M; Badoglio M; Scherer HU; Del Papa N; Daikeler T; Schmalzing M; Schroers R; Martin T; Pugnet G; Simoes B; Michonneau D; Marijt EWA; Lioure B; Olivier Bay J; Snowden JA; Rovira M; Huynh A; Onida F; Kanz L; Marjanovic Z; Farge D
    Haematologica; 2021 Feb; 106(2):375-383. PubMed ID: 31949011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis.
    Vonk MC; Marjanovic Z; van den Hoogen FH; Zohar S; Schattenberg AV; Fibbe WE; Larghero J; Gluckman E; Preijers FW; van Dijk AP; Bax JJ; Roblot P; van Riel PL; van Laar JM; Farge D
    Ann Rheum Dis; 2008 Jan; 67(1):98-104. PubMed ID: 17526554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of autologous stem cell transplantation for systemic sclerosis -- a single-center longterm experience in 26 patients with severe organ manifestations.
    Henes JC; Schmalzing M; Vogel W; Riemekasten G; Fend F; Kanz L; Koetter I
    J Rheumatol; 2012 Feb; 39(2):269-75. PubMed ID: 22247352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
    McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study.
    Farge D; Marolleau JP; Zohar S; Marjanovic Z; Cabane J; Mounier N; Hachulla E; Philippe P; Sibilia J; Rabian C; Chevret S; Gluckman E;
    Br J Haematol; 2002 Dec; 119(3):726-39. PubMed ID: 12437652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.
    van Laar JM; Farge D; Sont JK; Naraghi K; Marjanovic Z; Larghero J; Schuerwegh AJ; Marijt EW; Vonk MC; Schattenberg AV; Matucci-Cerinic M; Voskuyl AE; van de Loosdrecht AA; Daikeler T; Kötter I; Schmalzing M; Martin T; Lioure B; Weiner SM; Kreuter A; Deligny C; Durand JM; Emery P; Machold KP; Sarrot-Reynauld F; Warnatz K; Adoue DF; Constans J; Tony HP; Del Papa N; Fassas A; Himsel A; Launay D; Lo Monaco A; Philippe P; Quéré I; Rich É; Westhovens R; Griffiths B; Saccardi R; van den Hoogen FH; Fibbe WE; Socié G; Gratwohl A; Tyndall A;
    JAMA; 2014 Jun; 311(24):2490-8. PubMed ID: 25058083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiopulmonary function before and after cyclophosphamide treatment in severe systemic sclerosis: comparison of monthly intravenous bolus and autologous haematopoietic stem cell transplantation].
    Toledano C; Henegar C; Ilie D; Launay D; Tiev K; Marie I; Marjanovic Z; Emmerich J; Cabane J; Ménasché S; Farge D
    Rev Med Interne; 2005 Jun; 26(6):444-52. PubMed ID: 15936473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.
    Binks M; Passweg JR; Furst D; McSweeney P; Sullivan K; Besenthal C; Finke J; Peter HH; van Laar J; Breedveld FC; Fibbe WE; Farge D; Gluckman E; Locatelli F; Martini A; van den Hoogen F; van de Putte L; Schattenberg AV; Arnold R; Bacon PA; Emery P; Espigado I; Hertenstein B; Hiepe F; Kashyap A; Kötter I; Marmont A; Martinez A; Pascual MJ; Gratwohl A; Prentice HG; Black C; Tyndall A
    Ann Rheum Dis; 2001 Jun; 60(6):577-84. PubMed ID: 11350846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature.
    Eyraud A; Scouppe L; Barnetche T; Forcade E; Lazaro E; Duffau P; Richez C; Seneschal J; Truchetet ME;
    Br J Dermatol; 2018 Mar; 178(3):650-658. PubMed ID: 28906550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus.
    Burt RK; Traynor A; Statkute L; Barr WG; Rosa R; Schroeder J; Verda L; Krosnjar N; Quigley K; Yaung K; Villa Bs M; Takahashi M; Jovanovic B; Oyama Y
    JAMA; 2006 Feb; 295(5):527-35. PubMed ID: 16449618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
    Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
    Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study.
    van Bijnen S; de Vries-Bouwstra J; van den Ende CH; Boonstra M; Kroft L; Geurts B; Snoeren M; Schouffoer A; Spierings J; van Laar JM; Huizinga TW; Voskuyl A; Marijt E; van der Velden W; van den Hoogen FH; Vonk MC
    Ann Rheum Dis; 2020 Aug; 79(8):1084-1089. PubMed ID: 32409324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.
    Luznik L; Pasquini MC; Logan B; Soiffer RJ; Wu J; Devine SM; Geller N; Giralt S; Heslop HE; Horowitz MM; Jones RJ; Litzow MR; Mendizabal A; Muffly L; Nemecek ER; O'Donnell L; O'Reilly RJ; Palencia R; Schetelig J; Shune L; Solomon SR; Vasu S; Ho VT; Perales MA
    J Clin Oncol; 2022 Feb; 40(4):356-368. PubMed ID: 34855460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score.
    Ait Abdallah N; Wang M; Lansiaux P; Puyade M; Berthier S; Terriou L; Charles C; Burt RK; Hudson M; Farge D
    Bone Marrow Transplant; 2021 Sep; 56(9):2259-2267. PubMed ID: 34108673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The arguments favoring autologous haematopoietic stem cell transplantation in systemic scleroderma].
    Pugnet G
    Rev Med Interne; 2024 Feb; 45(2):104-108. PubMed ID: 38267322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.